Chrysin to Treat Cancer - Quick Reference Sheet
evipedia.ai ← Back

Chrysin to Treat Cancer

Created on 07/27/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A plant compound in honey, propolis, and passionflower that, in laboratory and animal studies, kills cancer cells, slows their growth, starves tumors, and boosts chemotherapy — yet has no human cancer trials. So little is absorbed when swallowed that even its estrogen-lowering vanished in people. Its main real-world concern is interfering with prescribed cancer drugs. (Full Review)

Protocol

Typical Dose
500–3,000 mg/day
Most often 500–1,000 mg once or twice daily; from supplement practice, not an oncology regimen
Frequency
Split, twice daily
Short plasma half-life (a few hours) favors split over a single daily dose
Administration
With a fat-containing meal
Often paired with piperine (black pepper) to slow breakdown of this poorly absorbed compound

Benefits

Contraindications
  • Active hormone therapy for hormone-sensitive cancer
  • Narrow-therapeutic-index chemotherapy
  • Pregnancy or breastfeeding
  • Known propolis or bee-product allergy
  • Significant liver impairment (Child-Pugh Class B or C)
    •
Key Interactions
  • Prescription drugs: aromatase inhibitors (anastrozole, letrozole, exemestane), SERMs (tamoxifen, raloxifene), UGT1A1 substrates (irinotecan, raloxifene), CYP1A2 substrates (theophylline, clozapine, tizanidine), CYP3A4 substrates (many chemotherapy agents)
  • OTC drugs cleared by glucuronidation or sulfation (acetaminophen)
  • Enzyme/transporter-inhibiting flavonoids (quercetin, apigenin, naringenin)
  • Estrogen-lowering supplements (DIM, calcium-D-glucarate)
  • Concurrent chemotherapy via efflux-pump inhibition
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Herb–drug interactions via enzyme and transporter inhibition; allergic reactions from bee-product sources
    •
  • Speculative: Estrogen suppression and endocrine effects; interference with hormone-dependent cancer therapy; gastrointestinal discomfort at high oral doses
    •

Monitoring

Marker Target Why
Estradiol (E2) Women (premenopausal, mid-cycle): ~50–250 pg/mL; men: ~10–40 pg/mL Detects any estrogen-lowering effect from aromatase inhibition
Total & Free Testosterone Men: ~500–900 ng/dL total; women: ~15–70 ng/dL total Tracks the flip side of aromatase activity
ALT & AST (liver enzymes) ~10–30 U/L Screens for liver stress from metabolism and interactions
Complete Blood Count (CBC) Within age- and sex-specific reference norms Safety monitoring, especially alongside chemotherapy
Thyroid-Stimulating Hormone (TSH) ~0.5–2.5 mIU/L Screens for any thyroid effect of high flavonoid intake

Cadence: Baseline before starting, then ~4–6 weeks after starting, then every 3–6 months while use continues; more often alongside chemotherapy or hormone therapy

Qualitative Assessment

  • Energy and vitality — day-to-day energy levels and exercise tolerance
  • Menopausal-type symptoms — hot flashes, joint aches, or mood changes that could signal unintended estrogen lowering
  • Digestive comfort — nausea, cramping, or stool changes at higher doses
  • Skin reactions — rash or itching that could indicate a propolis-related allergy
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.